Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis

Journal of Infectious Diseases

Volumn 206, Issue 8, 2012, Pages 1319-1329

  Sauer, Arnaud ^a,b   Pfaff, Alexander W ^b   Villard, Odile ^b   Creuzot Garcher, Catherine ^c   Dalle, Frédéric ^d   Chiquet, Christophe ^e   Pelloux, Hervé ^e   Speeg Schatz, Claude ^a   Gaucher, David ^a   Prevost, Gilles ^b   Bourcier, Tristan ^a   Candolfi, Ermanno ^b  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Service d'Ophtalmologie   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; TH1 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS; UPREGULATION; UVEITIS;

ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; PARASITE LOAD; PROSPECTIVE STUDIES; TH1 CELLS; TH17 CELLS; TOXOPLASMOSIS, ANIMAL; TOXOPLASMOSIS, OCULAR; UVEITIS, POSTERIOR;

EID: 84866933831     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis486     Document Type: Article

References (40)

1. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003; 136:973-88. (Pubitemid 37485762)
2. Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 2004; 137:1-17. (Pubitemid 38045181)
3. Garweg JG, Candolfi E. Immunopathology in ocular toxoplasmosis: facts and clues. Mem Inst Oswaldo Cruz 2009; 104:211-20.
4. de-la-Torre A, Rios-Cadavid AC, Cardozo-Garcia CM, Gomez-Marin JE. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol 2009; 93:1001-4.
5. Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006; 7:937-45. (Pubitemid 44263907)
6. Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005; 73:617-21. (Pubitemid 40041158)
7. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148:32-46. (Pubitemid 46365005)
8. Miyamoto M, Emoto M, Emoto Y, et al. Neutrophilia in LFA-1-deficient mice confers resistance to listeriosis: possible contribution of granulocyte-colony-stimulating factor and IL-17. J Immunol 2003; 170:5228-34. (Pubitemid 36554756)
9. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-27. (Pubitemid 32835046)
10. Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol 2011; 152:177-182 e1.
11. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-8. (Pubitemid 46889754)
12. Ke Y, Sun D, Jiang G, Kaplan HJ, Shao H. IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol 2011; 187:2130-9.
13. Lee YS, Amadi-Obi A, Yu CR, Egwuagu CE. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 2011; 132:492-502.
14. Lahmar I, Abou-Bacar A, Abdelrahman T, et al. Cytokine profiles in toxoplasmic and viral uveitis. J Infect Dis 2009; 199:1239-49.
15. Gaddi PJ, Yap GS. Cytokine regulation of immunopathology in toxoplasmosis. Immunol Cell Biol 2007; 85:155-9. (Pubitemid 46398730)
16. Lahmar I, Guinard M, Sauer A, et al. Murine neonatal infection provides an efficient model for congenital ocular toxoplasmosis. Exp Parasitol 2010; 124:190-6.
17. Jones LA, Alexander J, Roberts CW. Ocular toxoplasmosis: in the storm of the eye. Parasite Immunol 2006; 28:635-42. (Pubitemid 44722229)
18. Sauer A, Lahmar I, Scholler M, et al. [Development of murine models of ocular toxoplasmosis and preliminary results of ocular inflammatory transcriptome]. J Fr Ophtalmol 2009; 32:742-9.
19. Lu F, Huang S, Kasper LH. Interleukin-10 and pathogenesis of murine ocular toxoplasmosis. Infect Immun 2003; 71:7159-63. (Pubitemid 37475349)
20. Reischl U, Bretagne S, Kruger D, Ernault P, Costa JM. Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. BMC Infect Dis 2003; 3:7.
21. Charles E, Joshi S, Ash JD, et al. CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PDL1. Infect Immun 2010; 78:3484-92.
22. Guiton R, Vasseur V, Charron S, et al. Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice. J Infect Dis 2010; 202:427-35.
23. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677-88. (Pubitemid 43867371)
24. O'Quinn DB, Palmer MT, Lee YK, Weaver CT. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99:115-63.
25. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003; 74:179-85. (Pubitemid 38040414)
26. Horie S, Sugita S, Futagami Y, Yamada Y, Mochizuki M. Human retinal pigment epithelium-induced CD4+CD25+ regulatory T cells suppress activation of intraocular effector T cells. Clin Immunol 2010; 136:83-95.
27. Sugita S, Horie S, Nakamura O, et al. Retinal pigment epitheliumderived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol 2008; 181:7525-36.
28. Kitaichi N, Namba K, Taylor AW. Inducible immune regulation following autoimmune disease in the immune-privileged eye. J Leukoc Biol 2005; 77:496-502. (Pubitemid 40489525)
29. Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7:929-36. (Pubitemid 44263906)
30. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-33. (Pubitemid 44380299)
31. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89.
32. Kawanokuchi J, Shimizu K, Nitta A, et al. Production and functions of IL-17 in microglia. J Neuroimmunol 2008; 194:54-61.
33. Jia X, Hu M, Wang C, et al. Coordinated gene expression of Th17-and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis. Mol Vis 2011; 17:1493-507.
34. Yap GS, Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 1999; 201:240-7.
35. Munoz M, Heimesaat MM, Danker K, et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009; 206:3047-59.
36. Wilson MS, Feng CG, Barber DL, et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 2010; 184:4378-90.
37. Fekkar A, Ajzenberg D, Bodaghi B, et al. Direct genotyping of Toxoplasma gondii in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type II in France. J Clin Microbiol 2011; 49(4):1513-7.
38. Melo MB, Jensen KD, Saeij JP. Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends Parasitol 2011; 27 (11):487-95.
39. Sauer A, de la Torre A, Gomez-Marin J, et al. Prevention of retinochoroiditis in congenital toxoplasmosis: Europe versus South America. Pediatr Infect Dis J 2011; 30:601-3.
40. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56:95-113.